Nascent Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBIO research report →
About the company
Nascent Biotech, Inc. , a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma.
- CEO
- Sean Carrick
- IPO
- 2009
- Employees
- 2
- HQ
- Vero Beach, FL, US
Price Chart
- Market Cap
- $86.11K
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -0.30
- EV/EBITDA
- -0.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 268.93%
- ROIC
- 1662.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-2,088,000 · 25.46%
- EPS
- $-0.01 · 43.22%
- Op Income
- $-2,230,000
- FCF YoY
- 33.64%
- 52W High
- $0.13
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.72
- Avg Volume
- 2.54K
Get TickerSpark's AI analysis on NBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 24 | Karas Douglas John | other | 50,000 |
| Jun 30, 24 | HOLDEN LOWELL THOMAS | other | 96,000 |
| Jun 30, 24 | Carrick Sean | other | 192,000 |
| Mar 31, 24 | HOLDEN LOWELL THOMAS | other | 112,500 |
| Mar 31, 24 | Carrick Sean | other | 225,000 |
| Mar 31, 24 | Karas Douglas John | other | 27,100 |
| Dec 29, 23 | Carrick Sean | other | 239,300 |
| Dec 29, 23 | HOLDEN LOWELL THOMAS | other | 119,650 |
| Dec 29, 23 | Karas Douglas John | other | 28,935 |
| Sep 29, 23 | Karas Douglas John | other | 39,750 |
Our NBIO coverage
Recent articles, reports, and earnings notes.
No research on NBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBIO report →Similar companies
Peers in the same neighborhood.